• AMPLIRUN® ZIKA VIRUS
    RNA CONTROL

    Guarantee the quality of
    your molecular assays


  • New ZIKV-DENV-CHIKV IFA
    Easy-to-read results for the differential
    serological diagnosis by immunofluorescence


  • VirClia®
    Chemiluminescence in Monotest.
    The perfect combination for infectious serology.


  • Respiratory virus testing
    The complete solution for respiratory virus testing;
    screening and identification


Featured product

VIRCLIA® PLUS

VIRCLIA® PLUS

MEDLAB APAC 2018

Vircell will be attending the greatest exhibition of the IVD industry in the region, MEDLAB Asia Pacific in Singapore. 

Come to vist us at booth #P193 next 02-04 April.

More information

Development and production of diagnostic reagents for human infectious diseases

Vircell is a biotechnology company specialized in the development and production of ready to use reagents for human infectious diseases. We are present in laboratories of more than 80 countries worldwide on five continents. Vircell offers more than 400 references for the detection of bacteria, viruses, parasites and fungi by means of different techniques: ELISA, chemiluminescence, direct and indirect immunofluorescence, immunocapture agglutination, cell culture and Molecular Biology (oligochromatography and PCR controls).

Distributors

Vircell is present in laboratories of more than 80 countries worldwide. International Sales constitute one of the major sources of income for the company thanks to the constant work of our commercial team, who has a deep knowledge of the international market. If you need further information on the distribution of our products in your country, do not hesitate to contact us.

More information
20 February 2018 New VirClia training During last week, from February 13th to 15th, we had the pleasure of receiving seven ...
02 April 2018 MEDLAB Asia Pacific 2018 After the success of last edition, Vircell renews its participation in MEDLAB Asia Pacific, the ...

Newsletter

Sign up for our newsletter and you will receive our latest news in your e-mail